Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

LivaNova PLC Ordinary Shares (LIVN)

NASDAQ: LIVN · Electromedical & Electrotherapeutic Apparatus · Gloucester,

Our rating: Positive

Call changed from Neutral to Positive at $89.99, moderate conviction, November 6, 2026.

Breaks if: The Positive call breaks if revenue growth decelerates to below 6% for two consecutive reported quarters, or if trailing free cash flow falls below $80M — either would signal the franchise is losing commercial momentum faster than the current multiple assumes. On the upside, revenue growth sustained above 14% for two consecutive quarters, or a demonstrated path to GAAP operating profitability on a quarterly run-rate, would prompt a reassessment toward Conviction.

Key figures

Market value$5.0B
Revenue, last 12 months$1.5B
Net income, last 12 months$196M
Free cash flow, last 12 months$129M
Price to earnings25.5×
Free cash flow yield2.6%
Dividend yield0.0%
Operating margin10.7%
Return on equity15.5%
Beta to the S&P 5000.89
Volatility, annualized40.5%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$393M9.9%$0.11$43M
June 30, 2026$391M10.8%$1.93$35M
March 31, 2026$362M14.3%$0.40$926000.00
December 31, 2025$361M12.1%$0.56$50M
September 30, 2025$358M12.5%$0.49$62M
June 30, 2025$353M10.7%$0.50$48M
March 31, 2025$317M7.4%$-6.01$13M
December 31, 2024$322M3.8%$1.03$68M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 71 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.